Carl O\u0027Donnell
Carl O\u0027Donnell
CRITIC
img-contested
N/A
0 reviews
PUBLIC
img-contested
N/A
0 reviews

RECENT ARTICLES

Sort by:
No Rating
U.S. prepares push to reduce 'unnecessary' COVID-19 testing: official

U.S. prepares push to reduce 'unnecessary' COVID-19 testing: official

By , (Reuters) - The United States is preparing to issue guidance on reducing “unnecessary” testing for COVID-19 as it works to cut turnaround times for tests, a senior U.S. health official said on Thursday.Details of the guidance are still being hammered out but it would be aimed partly at discouraging COVID-19 patients who have completed home quarantine from getting retested before returning to work or school, said Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services.Speaking on a call with reporters, he said such unnecessary tests were...

July 16, 2020
Share
Save
Review
No Rating
Exclusive: J&J in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine

Exclusive: J&J in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine

By , More than a hundred vaccines are under development to try and stop the COVID-19 pandemic, and drugmakers including J&J are working to ramp up supply for their vaccines in the face of unprecedented demand.J&J has already agreed to prioritize an allocation to the United States as part of its funding agreement with the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), Wolk said.The Bill and Melinda Gates Foundation would focus on allocating any vaccine it acquired to developing countries, Wolk added. Reuters previously reported that J&J is also...

July 16, 2020
Share
Save
Review
No Rating
Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

By , (Reuters) - Wall Street is moving some bets on COVID-19 vaccines to large pharmaceutical companies with robust manufacturing capabilities, signaling that a love affair with small biotech firms might be ending after the sector’s best quarter in almost 20 years.Some of the selling was likely driven by end-of-quarter profit-taking, locking in dizzying gains in an otherwise turbulent market. Moderna and Inovio shares have risen nearly 200 percent and 540 percent in the year-to-date, respectively, greatly eclipsing gains for large pharmaceutical companies.Analysts say investors are changing...

July 3, 2020
Share
Save
Review
No Rating
Black Americans hospitalized for COVID-19 at four times the rate of whites, Medicare data shows

Black Americans hospitalized for COVID-19 at four times the rate of whites, Medicare data shows

By , (Reuters) - Black Americans enrolled in Medicare were around four times as likely as their white counterparts to be hospitalized for COVID-19, U.S. government data released on Monday showed, highlighting significant racial disparities in health outcomes during the pandemic.“The disparities in the data reflect longstanding challenges facing minority communities and low income older adults,” said Seema Verma, administrator of the Centers for Medicare & Medicaid Services (CMS), which released the data.The data showed that more than 325,000 Medicare beneficiaries were diagnosed with...

June 22, 2020
Share
Save
Review
No Rating
Pfizer, BioNTech set to begin U.S. coronavirus vaccine trial

Pfizer, BioNTech set to begin U.S. coronavirus vaccine trial

By , The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline.The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000.There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under...

May 5, 2020
Share
Save
Review
No Rating
Johnson & Johnson to stop selling talc baby powder in U.S. and Canada

Johnson & Johnson to stop selling talc baby powder in U.S. and Canada

By , (Reuters) - Johnson & Johnson will stop selling its talc Baby Powder in the United States and Canada, it announced on Tuesday, saying demand had fallen in the wake of what it called “misinformation” about the product’s safety amid a barrage of legal challenges.J&J faces more than 19,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with asbestos, a known carcinogen. Many are pending before a U.S. district judge in New Jersey.“I wish my mother could be here to see this day,” said Crystal Deckard, whose mother Darlene...

May 20, 2020
Share
Save
Review
  • Total 6 items
  • 1
OUTLETS
reuters.com

reuters.com

CRITIC
img-trusted
100%
PUBLIC
img-trusted
80%